ArticleESMO open2022

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.

C Le Tourneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.